Pillai Krishna, Pourgholami Mohammad H, Chua Terence C, Morris David L
Department of Surgery, University of New South Wales, St. George Hospital, Kogarah, NSW - Australia.
Int J Biol Markers. 2013 Sep 27;28(3):303-12. doi: 10.5301/jbm.5000038.
Overexpression of MUC1 predicts poor survival in most cancers. Routine immunohistochemical detection of MUC1 is performed for differential diagnosis in malignant peritoneal mesothelioma (MPM). However, the prognostic significance of MUC1 in MPM has not been determined.
We investigated MUC1 expression and other prognostic factors in relation to survival in 42 patients (20 males and 22 females) for whom archival samples were available, using immunohistochemistry. MUC1 was expressed in 38/42 (90%) patients. Its prognostic significance was statistically analyzed using the Kaplan-Meier method.
High expression of MUC1 (immunohistochemical score of 5-8), was correlated with poor survival in several categories: all subtypes of tumors (p=0.001), male gender (p=0.017), female gender (p=0.001), epitheloid tumors (p=0.001), epitheloid tumors in males (p=0.005), epitheloid tumors in females (p=0.003), and age at diagnosis (AAD) <60 years (p=0.001). Amongst the other clinicopathological variables, univariate analysis also showed that male gender (p=0.007), sarcomatoid histology (p=0.001), peritoneal cancer index (PCI) ≥20 (p=0.013) and AAD ≥60 (p=0.001), correlated with poor survival. Multivariate analysis showed that only AAD ≥60 (p=0.049) was an independent prognostic factor, and that high MUC1 expression significantly correlated with the following categories: all subtypes of tumors (p=0.001), male gender (p=0.002), female gender (p=0.031), epitheloid tumors (p=0.031), and AAD <60y (p=0.012).
AAD and high MUC1 expression in the tumor are indicators of poor prognosis. MUC1 evaluation by immunohistochemistry may serve as a useful prognostic tool in MPM, but may need further confirmation in a larger patients' cohort.
MUC1的过表达在大多数癌症中预示着较差的生存率。在恶性腹膜间皮瘤(MPM)中,常规进行MUC1的免疫组织化学检测以用于鉴别诊断。然而,MUC1在MPM中的预后意义尚未确定。
我们使用免疫组织化学方法研究了42例(20例男性和22例女性)有存档样本患者的MUC1表达及其他与生存相关的预后因素。42例患者中有38例(90%)表达MUC1。使用Kaplan-Meier方法对其预后意义进行统计学分析。
MUC1高表达(免疫组织化学评分为5 - 8)与以下几类患者的较差生存率相关:所有肿瘤亚型(p = 0.001)、男性(p = 0.017)、女性(p = 0.001)、上皮样肿瘤(p = 0.001)、男性上皮样肿瘤(p = 0.005)、女性上皮样肿瘤(p = 0.003)以及诊断时年龄(AAD)<60岁(p = 0.001)。在其他临床病理变量中,单因素分析还显示男性(p = 0.007)、肉瘤样组织学(p = 0.001)、腹膜癌指数(PCI)≥20(p = 0.013)和AAD≥60(p = 0.001)与较差生存率相关。多因素分析显示只有AAD≥60(p = 0.049)是一个独立的预后因素,并且MUC1高表达与以下几类显著相关:所有肿瘤亚型(p = 0.001)、男性(p = 0.002)、女性(p = 0.031)、上皮样肿瘤(p = 0.031)以及AAD <60岁(p = 0.012)。
肿瘤中的AAD和MUC1高表达是预后不良的指标。通过免疫组织化学评估MUC1可能是MPM中一种有用的预后工具,但可能需要在更大的患者队列中进一步证实。